A phase II multicenter study to assess the tolerability and efficacy of the addition of bevacizumab standard induction therapy in AML and high risk MDS above 60 years.

Trial Profile

A phase II multicenter study to assess the tolerability and efficacy of the addition of bevacizumab standard induction therapy in AML and high risk MDS above 60 years.

Completed
Phase of Trial: Phase II

Latest Information Update: 09 Oct 2012

At a glance

  • Drugs Bevacizumab (Primary) ; Cytarabine; Daunorubicin
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 16 Sep 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
    • 21 Feb 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top